Dimitri Azar - Novartis Non-Executive Independent Director
| NVS Stock | USD 98.35 1.07 1.10% |
Director
Dr. Dimitri Azar, M.D., was NonExecutive Independent Director of Novartis Inc. since February 2012. He is Member of the Governance, Nomination and Corporationrationrate Responsibilities Committee and the Research Development Committee. Dr. Azar is senior director of ophthalmological innovation at Verily Life Sciences. He has also served as dean of the University of Illinois at Chicago College of Medicine in the United States since 2011, and as professor of ophthalmology, bioengineering and pharmacology at UIC since 2006. From 2006 to 2011, he was head of the Department of Ophthalmology and Visual Sciences at UIC. He is a member of the American Ophthalmological Society, former president of the Chicago Ophthalmological Society, and presidentelect of the Chicago Medical Society. Additionally, he is on the board of the Tear Film and Ocular Surface Society, the board of Verb Surgical Inc., and the scientific board of Verily all based in the United States. Dr. Azar began his career at the American University of Beirut Medical Center in Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. His research on matrix metalloproteinases in corneal wound healing and angiogenesis was funded by the US National Institutes of Health since 1993. Dr. Azar practiced at the Wilmer Eye Institute at the Johns Hopkins Hospital School of Medicine in the US, and then returned to the Massachusetts Eye and Ear Infirmary as director of cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003 since 2012.
| Age | 59 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Address | Lichtstrasse 35, Basel, Switzerland, 4056 |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has Return on Asset of 0.0865 % which means that on every $100 spent on assets, it made $0.0865 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1983 %, implying that it generated $0.1983 on every 100 dollars invested. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novartis' Return On Tangible Assets are comparatively stable compared to the past year. Return On Capital Employed is likely to gain to 0.14 in 2024, whereas Return On Assets are likely to drop 0.11 in 2024. At this time, Novartis' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 73.2 B in 2024, whereas Total Current Assets are likely to drop slightly above 29.9 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Klaus Pohle | Sanofi ADR | 76 | |
| Franklyn Prendergast | Eli Lilly and | 70 | |
| Kelly Kramer | Gilead Sciences | 50 | |
| Michael Eskew | Eli Lilly and | 71 | |
| Glenn Tilton | AbbVie Inc | 72 | |
| Manvinder Banga | GlaxoSmithKline PLC ADR | 62 | |
| Gayle Wilson | Gilead Sciences | 75 | |
| JeanPhilippe Courtois | AstraZeneca PLC ADR | 54 | |
| Roxanne Austin | AbbVie Inc | 60 | |
| James Quincey | Pfizer Inc | 56 | |
| John Noseworthy | Merck Company | 66 | |
| Jose Baselga | Bristol Myers Squibb | 57 | |
| Uwe Bicker | Sanofi ADR | 69 | |
| Vivienne Cox | GlaxoSmithKline PLC ADR | 61 | |
| Peter Wendell | Merck Company | 70 | |
| Pius Baschera | Roche Holding Ltd | 65 | |
| Pamela Craig | Merck Company | 64 | |
| Jackson Tai | Eli Lilly and | 71 | |
| JeanRene Fourtou | Sanofi ADR | 75 | |
| John Bell | Roche Holding Ltd | 65 | |
| Jesse Goodman | GlaxoSmithKline PLC ADR | 69 | |
Management Performance
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0865 |
Novartis AG ADR Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charlotte Wieser, Corporate Secretary | ||
| Ton Buechner, Non-Executive Independent Director | ||
| Robert PharmD, Chief Officer | ||
| Verena Briner, Non-Executive Independent Member of the Board | ||
| Karen Hale, Chief Legal Officer, Member of the Executive Board | ||
| Chris Ilsley, President CEO | ||
| Steven Baert, Chief People & Organization Officer, Member of the Executive Committee | ||
| Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee | ||
| Richard Francis, Member of the Executive Committee and Division Head, Sandoz | ||
| Daniel Vasella, Honorary Chairman of the Board | ||
| Pierre Landolt, Member of the Board of Directors | ||
| Elizabeth Doherty, Non-Executive Independent Director | ||
| Erwin Vanhaecke, Head Novartis Group Quality | ||
| Victor Bulto, President Innovative Medicines US, Member of the Executive Board | ||
| Fiona Marshall, President Research | ||
| Elizabeth Barrett, CEO, Novartis Oncology | ||
| Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) | ||
| Charlotte PamerWieser, Corporate Secretary | ||
| Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | ||
| Shreeram MD, President Officer | ||
| Samir Shah, Global Head Investor Relations | ||
| David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals | ||
| Srikant Datar, Non-Executive Independent Director | ||
| MarieFrance Tschudin, President, Innovative Medicines International and Chief Commercial Officer, Member of the Executive Board | ||
| Samir MD, Global Relations | ||
| Simon Moroney, Non-Executive Independent Director | ||
| Francesco Balestrieri, Chief Executive Officer of Sandoz, Member of the Executive Committee | ||
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| Paul Penepent, Head Accounting | ||
| Joerg Reinhardt, Independent Non-Executive Chairman of the Board | ||
| Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee | ||
| Brian McNamara, Member of the Management Board, Division Head, Novartis OTC | ||
| Andrews C, Non-Executive Independent Director | ||
| Michele Galen, Head Communications | ||
| Charles Sawyers, Non-Executive Independent Member of the Board | ||
| Etienne Jousseaume, Cell Access | ||
| John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee | ||
| Dimitri Azar, Non-Executive Independent Director | ||
| Frans Houten, Non-Executive Independent Director | ||
| Nancy Andrews, Non-Executive Independent Director | ||
| Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee | ||
| Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board | ||
| Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | ||
| Robert Weltevreden, Head of Customer and Technology Solutions, Member of the Executive Committee | ||
| Patrick MD, President International | ||
| Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland | ||
| Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Alex Krauer, Honorary Chairman of the Board | ||
| Michael Ball, CEO of Alcon, Member of the Executive Committee | ||
| Jeffrey George, Member of the Executive Committee and Division Head, Sandoz | ||
| Patrice Bula, Non-Executive Independent Director | ||
| Linda MD, Global Development | ||
| Peter Kornicker, Chief Compliance Officer | ||
| Andreas Planta, Non-Executive Independent Director | ||
| Joseph Jimenez, CEO, Member of the Executive Committee | ||
| Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director | ||
| William Winters, Non-Executive Independent Member of the Board | ||
| Ann Fudge, Non-Executive Independent Director | ||
| Robert Kowalski, Chief People and Organization Officer | ||
| George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility | ||
| Paul Arkel, Head of Corporate Strategy and External Affairs | ||
| James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | ||
| Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee | ||
| Aharon Gal, Chief Officer | ||
| Vasant MD, Chief Officer | ||
| Felix Ehrat, General Counsel and General Counsel of Novartis International Ag | ||
| Harry Kirsch, Chief Financial Officer, Member of the Executive Committee | ||
| Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics | ||
| Bridgette Heller, Non-Executive Independent Director |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0865 | ||||
| Profit Margin | 0.32 % | ||||
| Operating Margin | 0.31 % | ||||
| Current Valuation | 216.21 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Institutions | 6.92 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | 9.22 X | ||||
| Price To Book | 4.10 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.215 | Dividend Share 3.919 | Earnings Share 4.1 | Revenue Per Share 23.168 | Quarterly Revenue Growth 0.097 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.